The regulatory adaptive status in hypertensive patients with congestive heart failure with preserved left ventricular ejection fraction: the effects of fosinopril versus zofenopril

Objective. To evaluate the impact of fosinopril versus zofenopril on the regulatory adaptive status (RAS) in hypertensive patients with chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction (EF).

Design and methods. The study inclded 67 hospitalized patients with hypertension (HTN) and CHF I–II NYHA functional classes with LV EF ≥ 50 %, who were randomized into two groups for treatment with fosinopril (13,8 ± 4,1 mg/day, n = 32) or zofenopril (17,9 ± 5,9 mg/day, n = 35). All patients additionally received nebivolol (7,1 ± 1,9 and 6,9 ± 1,8 mg/day), and if needed, atorvastatin and acetylsalicylic acid were prescribed. At baseline and after 24 weeks, we performed quantitative assessment of RAS-regulatory-adaptive capabilities (by cardio-respiratory coupling test), echocardiography, treadmill test, six-minute walking test, assessment of the N-terminal brain natriuretic pro-peptide level in blood plasma, subjective evaluation of quality of life (QL).

Results. Fosinopril versus zofenopril led to a greater improvement of RAS (by 69,0%, p < 0,01 versus 41,1%, p < 0,01) and to a higher increase in tolerance to physical activity: longer distance in a six-minute walk test (by 28,1 %, p < 0,05 versus 25,9 %, p < 0,05), improvement in functional class of CHF (from II to I in 56 % of patients, in 25 % CHF was not registered versus change from II to I in 42 % of patients, and no CHF in 14 %). In both groups, cardiac diastolic function improved (decreased VE/Ve by 39,5%, p < 0,01 and 37,8%, p < 0,01), neurohumoral hyperactivity reduced (NT-proBNP decreased by 40,6 %, p < 0,01 and 39,4 %, p < 0,01), and subjective QL increased (decrease in the amount of negative points by 69,3%, p < 0,01, and 64,9 %, p < 0,01).

 Conclusions. In HTN patients with CHF with preserved LV EF, fosinopril versus zofenopril may be preferable due to a greater impact on regulatory and adaptive capabilities. 

1. Mareev VYu, Fomin IV, Ageev FT, Begrambekova YuL, Vasyuk YuA, Garganeeva AA et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia = Cardiology. 2018;58(6S):8–158. doi:10.18087/cardio.2475. In Russian.

2. Genet M, Lee LC, Baillargeon B, Guccione JM, Kuhl E. Modeling pathologies of diastolic and systolic heart failure. Ann Biomed Eng. 2016;44(1):112–127. doi.org/10.1007/s10439-015-1351-2

3. Nicoara A, Jones-Haywood M. Diastolic heart failure: diagnosis and therapy. Curr Opin Anaesthesiol. 2016;29(1):61–67. doi:10.1097/ACO.0000000000000276

4. Ahmed A, Rich MW, Zile M, Sanders PW, Patel K, Zhang Y et al. Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am J Med. 2013;126 (2):150–161. doi:10.1016/j.amjmed.2012.06.031

5. Wieser M, Rhyner D, Martinelli M, Suter T, Schnegg B, Bösch C et al. Pharmacological therapy of heart failure with reduced ejection fraction. Ther Umsch. 2018;75(3):180–186. doi:10.1024/0040-5930/a000986

6. Serobyan AO, Alukhanyan LO, Skorikova LA, Zabolotskikh NV, Alukhanyan OA, Potyagailo EG. Regulatory and adaptive capabilities of the body in various forms of chronic periodontitis in the period of exacerbation. Kubanskij nauchnij vestnik. 2016;(6):123–7. In Russian.

7. Tregubov VG, Pokrovsky VM, Kanorsky SG. Quantitative assessment of regulatory-adaptive status in determining the severity of chronic heart failure. Clin Med. 2012;90(8):32–35. In Russian.

8. Mareev VYu, Ageev FT, Arutyunov GP, Koroteev AV, Mareev YuV, Ovchinnikov AG et al. National guidelines for the diagnosis and treatment of CHF (fourth revision). J Heart Failure. 2013:14(7):379–472. In Russian.

9. Pokrovskij VM, Abushkevich VG, Gorbunov RV, Companiets OG, Kutsenko II, Lazareva LA et al. Cardiac-respiratory synchronism in the assessment of regulatory and adaptive capabilities of the body. Krasnodar: Kuban-Kniga, 2010. 243 p. In Russian.

10. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocadiogr. 2016;29(4):277–314.

11. Skotnikov AS, Yudina DYu, Staxnev EYu. Antihypertensive treatment of comorbid patient: what are the challenges in the selection of the drug? Attending Physician. 2018;2:24–30. In Russian.

12. Piepho RW. Overview of the angiotensin-convertingenzyme inhibitors. Am J Health Syst Pharm. 2000;57(1):3–7.

13. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809–2816. doi:10,1161/01.CIR.0000146378.65439.7A

14. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21(4):597–603.

15. Carpov YuA, Mareev VYu, Chazova IE. Russian programs to evaluate the effectiveness of treatment with fosinopril in patients with arterial hypertension and heart failure. Project THREE F (FLAG, FASON, FAGOT). J Heart Fail. 2003;4(5):261–265. In Russian.

16. Borghi C, Omboni S, Reggiardo G, Bacchelli S, Degli Esposti D, Ambrosioni E. Efficacy of zofenopril in combination with amlodipine in patients with acute myocardial infarction: a pooled individual patient data analysis of four randomized, doubleblind, controlled, prospective studies. Curr Med Res Opin. 2018;34 (10):1869–1874. doi:10.1080/03007995.2018.1496076

17. Preobrazhenskij DV, Sidorenko BA, Bugrimova MA, Pataraya SA, Shaipova AM. Zofenopril (Zokardis) is a cardioselective inhibitor of angiotensin converting enzyme: features of clinical pharmacology and application prospects in the treatment of cardiovascular diseases. Russian Medical Journal. 2007;4:296. In Russian.

18. Pokrovskii VM, Polischuk LV. Cardiorespiratory synchronism in estimation of regulatory and adaptive organism status. J Integr Neurosci. 2016;15(1):19–35. doi:10.1142/S0219635216500060

19. Rokotyanskaya ES. Influence of therapy of chronic heart failure of the III functional class on the regulatory and adaptive status. Kubanskij Nauchnij Vestnik. 2014;(5):102–108. doi:10.25207/1608-6228-2014-5-102-108. In Russian.

20. Tregubov VG, Shubitidze IZ, Kanorskij SG, Pokrovskij VM. Results of a comparative study of the effectiveness of treatment with nebivolol and sotalol in patients with ventricular arrhythmias. Clin Med. 2017;95(11):1050–1056. doi:10.18821/0023–2149-2017-95-11-1050-1056. In Russian.